Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 35, 2021 - Issue 1
Submit an article Journal homepage
1,239
Views
0
CrossRef citations to date
0
Altmetric
Articles

Screening for depression among chronically ill patients in community pharmacy settings: a pilot study in Bulgaria

Yoanna Vutovaa Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaView further author information
,
Maria Kamushevaa Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4379-5283View further author information
ORCID Icon,
Desislava Ignatovab Department of Psychiatry and Medical Psychology, Faculty of Medicine, Medical University of Sofia, Sofia, BulgariaView further author information
&
Petya Milushewaa Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaView further author information
Pages 1393-1400 | Received 16 Jul 2021, Accepted 09 Sep 2021, Published online: 08 Nov 2021

References

  • Kamusheva M, Ignatova D, Golda A, et al. The potential role of the pharmacist in supporting patients with depression – a literature-based point of view. Integr Pharm Res Pract. 2020;9:49–63.
  • Reddy MS. Depression: the disorder and the burden. Indian J Psychol Med. 2010;32(1):1–2.
  • Diagnostic and Statistical Manual of Mental Disorders (DSM-5). available at https://www.psychiatry.org/psychiatrists/practice/dsm.
  • Hurley LL, Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox Res. 2013;23(2):131–144.
  • Mitkov J, Kondeva-Burdina M, Zlatkov A. Synthesis and preliminary hepatotoxicity evaluation of new caffeine-8-(2-thio)-propanoic hydrazid-hydrazone derivatives. PHAR. 2019;66(3):99–106.
  • Bajpai A, Verma AK, Srivastava, et al. Oxidative stress and major depression. J Clin Diagn Res. 2014;8(12):CC04–CC7.
  • Kasabova-Angelova A, Tzankova D, Mitkov J, et al. Xanthine derivatives as agents affecting non-dopaminergic neuroprotection in Parkinson’s disease. Curr Med Chem. 2020;27(12):2021–2036.
  • Kasabova-Angelova A, Kondeva-Burdina M, Mitkov J, et al. Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides. Braz. J. Pharm. Sci. 2020;56.
  • Van den Berg M, Smit F, Vos T, et al. Cost-effectiveness of opportunistic screening and minimal contact psychotherapy to prevent depression in primary care patients. PLoS Onе. 2011;6(8):e22884.
  • Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–1078.
  • Hermanns N, Caputo S, Dzida G, et al. Screening, evaluation and management of depression in people with diabetes in primary care. Prim Care Diabetes. 2013;7(1):1–10.
  • Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000;23(7):934–942.
  • Funk K, Hudson S, Tingen J. Use of clinical pharmacists to perform depression screening. Qual Prim Care. 2014;22(5):249–250.
  • Knox ED, Dopheide JA, Wincor MZ, et al. Depression screening in a university campus pharmacy: a pilot project. J Am Pharm Assoc. 2006;46(4):502–506.
  • Vassileva M, Kamusheva M, Manova M, et al. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. Expert Rev Pharmacoecon Outcomes Res. 2019;19(6):733–742.
  • Patient Health Questionnaire (PHQ-9). Available at https://www.med.umich.edu/1info/FHP/practiceguides/depress/phq-9.pdf.
  • Naseva E, Bratovanova S, Stoycheva M, et al. Health-related quality of life – Comparasion of the methods for EQ-5D calculations. Gen Medicine. 2014;XVI(3):3–9.
  • EQ-5D-5L Crosswalk value sets. October 2019. Available at https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/crosswalk-index-value-calculator/.
  • Kondova A, Todorova A, Tsvetkova A, et al. Screening and risk assessment for depression in community pharmacy – pilot study. JofIMAB. 2018;24(1):1928–1931.
  • Wilson C, Twigg G. Pharmacist-led depression screening and intervention in an underserved, rural, and multi-ethnic diabetic population. J Am Pharm Assoc (2003). 2018;58(2):205–209.
  • Rosser S, Frede S, Conrad WF, et al. Development, implementation, and evaluation of a pharmacist-conducted screening program for depression. J Am Pharm Assoc (2003). 2013;53(1):22–29. PMID: 23636152.
  • Elkhodr S, Saba M, O’Reilly C, et al. The role of community pharmacists in the identification and ongoing management of women at risk for perinatal depression: a qualitative study. Int J Soc Psychiatry. 2018;64(1):37–48.
  • Miller P, Newby D, Walkom E, et al. Depression screening in adults by pharmacists in the community: a systematic review. Int J Pharm Pract. 2020;28(5):428–440.
  • Roy Morgan News Poll. Images of Professions Survey, 2014. Available at [cited 15 April 2014]. http://www.roymorgan.com/fifindings/5531-image-of-professions-2014-201404110537.
  • Mey A, Knox K, Kelly F, et al. Trust and safe spaces: mental health consumers’ and carers’ relationships with community pharmacy staff. Patient. 2013;6(4):281–289.
  • Capoccia KL, Boudreau DM, Blough DK, et al. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. Am J Health Syst Pharm. 2004;61(4):364–372.
  • Ballou J, Chapman A, Roark A, et al. Conducting depression screenings in a community pharmacy: a pilot comparison of methods. J Am Coll Clin Pharm. 2019;2(4):366–372.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.